Influence of acupoint-injection on TXB2 and 6-keto-PGF1a in patients with pseudobulbar palsy：a randomized controlled trial
10.1007/s11726-017-0969-z
- VernacularTitle:穴位注射对假性延髓麻痹患者TXB2和6-keto-PGF1a的影响的随机对照试验
- Author:
Jiye LIU
;
Yinghua CHEN
- Keywords:
Point,Fengchi (GB 20);
Hydro-acupuncture;
Acupoint Therapy;
Pseudobulbar Palsy;
Deglutition Disorders;
Brain Ischemia;
Thromboxane B2
- From:
Journal of Acupuncture and Tuina Science
2017;15(1):22-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To prove the feasibility and validity ofXing Nao Jing acupoint-injection (XNJ-AI) at Fengchi (GB 20) for pseudobulbar palsy caused by ischemic stroke (PBP-IS).
Methods:An assessor-blinded, two-parallel-group, randomized controlled trial was conducted, and the patients with PBP-IS were recruited and randomly divided into two groups. Patients in the control group received oral aspirin (100 mg per day for 2 weeks). In addition to oral aspirin; patients in the treatment group received XNJ-AI at Fengchi (GB 20), once a day, for two weeks. The primary outcome was assessed by the water-swallowing test (WST). Thromboxane B2 (TXB2) and 6-keto-prostaglandin F1a (6-keto-PGF1a) in plasma were measured before and after the treatment.
Results:In the treatment group, the percentage of swallowing function no less than grade 3 before and after the treatment was 32% and 88%, respectively; in the control group, it was 28% and 76% before and after the treatment, respectively; the difference after the treatment between the two groups was statistically significant (P<0.05). There were statistical differences between pre- and post-treatment levels of plasma TXB2and 6-keto-PGF1αin the two groups (bothP<0.05). After the treatment, there were significant differences in the levels of plasma TXB2 and 6-keto-PGF1α between the two groups (bothP<0.05).
Conclusion:XNJ-AI at Fengchi (GB 20) can improve the patients’ swallowing function and balance the levels of TXB2 and 6-keto-PGF1α in plasma.
